Brief: Cerenis Therapeutics FY Operating Loss Widens To 7.1 Million Euros

Abionyx Pharma SA

24/01/2019 18:20

Jan 24 (Reuters) - CERENIS THERAPEUTICS HOLDING SA
 CEREN.PA :
    * CASH POSITION OF EUR 11.5 MILLION AT DECEMBER 31, 2018
    * SUCCESS OF TARGET PHASE II STUDY DEMONSTRATES ABILITY OF
CER-001, AN HDL MIMETIC, TO TARGET TUMORS IN PATIENTS WITH
ESOPHAGEAL CANCER
    * MISSED PRIMARY ENDPOINT IN TANGO PHASE III STUDY
    * RESULTS OF PHASE I STUDY, ASSESSING CER-209 IN NAFLD/NASH,
CONFIRM DRUG CANDIDATE'S FAVORABLE SAFETY AND TOLERANCE PROFILE
    * FY OPERATING LOSS EUR 7.1 MILLION VERSUS LOSS OF EUR 6.6
MILLION
YEAR AGO
    * FY REVENUE EUR 0.2 MILLION VERSUS EUR 0 MILLION YEAR AGO
    * FY NET LOSS EUR 6.3 MILLION VERSUS LOSS OF EUR 5.0 MILLION
YEAR
AGO

Source text for Eikon:  ID:nBw2YFTmRa 
Further company coverage:  CEREN.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))